GSK’s severe asthma therapy Nucala gets EU nod – PMLiVE


PMLiVE

GSK's severe asthma therapy Nucala gets EU nod
PMLiVE
GlaxoSmithKline's first-in-class interleukin-5 (IL-5) inhibitor Nucala has been approved in the EU as a steroid-sparing therapy for patients with severe asthma. Nucala (mepolizumab) has been cleared by the European Commission as an add-on treatment for …

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.